The p53-MDM2/MDMX axis - A chemotype perspective

被引：60

作者：

Khoury, Kareem ^{[1
]}

Popowicz, Grzegorz M. ^{[2
]}

Holak, Tad A. ^{[2
]}

Doemling, Alexander ^{[1
]}

机构：

[1] Univ Pittsburgh, Dept Pharmaceut Sci, Drug Discovery Inst, Pittsburgh, PA 15260 USA

[2] Max Planck Inst Biochem, D-8000 Munich, Germany

来源：

MEDCHEMCOMM | 2011年 / 2卷 / 04期

关键词：

PROTEIN-PROTEIN INTERACTION; SUPPRESSOR TRANSACTIVATION DOMAIN; SMALL-MOLECULE ANTAGONISTS; STRUCTURE-BASED DESIGN; WILD-TYPE P53; MDM2; INHIBITORS; CANCER-THERAPY; IN-VIVO; IDENTIFY DISRUPTORS; HDM2; ANTAGONISTS;

D O I：

10.1039/c0md00248h

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the A-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.

引用

页码：246 / 260

页数：15

共 116 条

[1]

3 DIMENSIONAL PHARM, 2004, Patent No. 2004096134

[2] Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction [J].

Allen, John G. ;

Bourbeau, Matthew P. ;

Wohlhieter, G. Erich ;

Bartberger, Michael D. ;

Michelsen, Klaus ;

Hungate, Randall ;

Gadwood, Robert C. ;

Gaston, Rick D. ;

Evans, Bruce ;

Mann, Larry W. ;

Matison, Michael E. ;

Schneider, Stephen ;

Huang, Xin ;

Yu, Dongyin ;

Andrews, Paul S. ;

Reichelt, Andreas ;

Long, Alexander M. ;

Yakowec, Peter ;

Yang, Evelyn Y. ;

Lee, Tani Ann ;

Oliner, Jonathan D. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7044-7053

[3]

ANDREEFF M, 2010, AM SOC HEM ANN M SAN

[4]

[Anonymous], [No title captured], Patent No. [WO 2008/141975, 2008141975]

[5] Design and modular parallel synthesis of a MCR derived α-helix mimetic protein-protein interaction inhibitor scaffold [J].

Antuch, W ;

Menon, S ;

Chen, QZ ;

Lu, YC ;

Sakamuri, S ;

Beck, B ;

Schauer-Vukasinovic, V ;

Agarwal, S ;

Hess, S ;

Dömling, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1740-1743

[6]

Bartkovitz D.J., 2009, Chiral Cis-Imidazolines International Publication, Patent No. [2009/047161, 2009047161]

[7] Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant [J].

Basse, Nicolas ;

Kaar, Joel L. ;

Settanni, Giovanni ;

Joerger, Andreas C. ;

Rutherford, Trevor J. ;

Fersht, Alan R. .

CHEMISTRY & BIOLOGY, 2010, 17 (01) :46-56

[8] Discovery of pyrroloimidazoles as agents stimulating neurite outgrowth [J].

Beck, Barbara ;

Leppert, Christian A. ;

Mueller, Bernhard K. ;

Doemling, Alexander .

QSAR & COMBINATORIAL SCIENCE, 2006, 25 (5-6) :527-535

[9]

BECK HP, 2010, BIOORG MED CHEM LETT

[10] A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53 [J].

Bernal, Federico ;

Wade, Mark ;

Godes, Marina ;

Davis, Tina N. ;

Whitehead, David G. ;

Kung, Andrew L. ;

Wahl, Geoffrey M. ;

Walensky, Loren D. .

CANCER CELL, 2010, 18 (05) :411-422

← 1 2 3 4 5 6 7 8 9 10 →